Quick Answer
Protagonist Therapeutics, Inc reported Net Income Loss of -$130.15 million for the year ending 2025.
- Protagonist Therapeutics, Inc showed a decrease of -147.3% in Net Income Loss from 2024 to 2025.
- This data is from Protagonist Therapeutics, Inc's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$2.70 million | Q2 2015: -$3.22 million | Q3 2015: -$3.45 million | Q4 2015: -$5.49 million | Q1 2016: -$11.75 million | Q2 2016: -$7.10 million | Q3 2016: -$7.08 million | Q4 2016: -$11.25 million | Q1 2017: -$14.10 million | Q2 2017: -$14.98 million | Q3 2017: -$4.83 million | Q4 2017: -$3.05 million | Q1 2018: -$7.66 million | Q2 2018: -$8.66 million | Q3 2018: -$8.74 million | Q4 2018: -$13.87 million | Q1 2019: -$14.10 million | Q2 2019: -$29.17 million | Q3 2019: -$16.41 million | Q4 2019: -$17.50 million | Q1 2020: -$20.08 million | Q2 2020: -$19.42 million | Q3 2020: -$7.76 million | Q1 2021: -$24.00 million | Q2 2021: -$30.84 million | Q3 2021: -$33.80 million | Q1 2022: -$20.93 million | Q2 2022: -$41.04 million | Q3 2022: -$31.23 million | Q1 2023: -$33.73 million | Q2 2023: -$38.46 million | Q3 2023: -$34.11 million | Q1 2024: $207.34 million | Q2 2024: -$30.62 million | Q3 2024: -$33.21 million | Q1 2025: -$11.66 million | Q2 2025: -$34.77 million | Q3 2025: -$39.34 million.
- Over the full 12 years of available data (2014 to 2025), Protagonist Therapeutics, Inc's Net Income Loss has declined by 1,075.5%.
- Historical annual values: Fiscal year 2025: -$130.15 million | Fiscal year 2024: $275.19 million | Fiscal year 2023: -$78.96 million | Fiscal year 2022: -$127.39 million | Fiscal year 2021: -$125.55 million | Fiscal year 2020: -$66.15 million | Fiscal year 2019: -$77.19 million | Fiscal year 2018: -$38.92 million | Fiscal year 2017: -$36.96 million | Fiscal year 2016: -$37.18 million | Fiscal year 2015: -$14.86 million | Fiscal year 2014: -$11.07 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: